Pitavastatin for Pancreatic Cancer

This trial tests whether adding Pitavastatin, a cholesterol-lowering medication, to standard cancer treatments can benefit individuals with unresectable pancreatic adenocarcinoma, a type of pancreatic cancer that cannot be surgically removed. The researchers aim to determine the safest dose of Pitavastatin that can be combined with the cancer drugs Gemcitabine and Nab-paclitaxel. Suitable candidates for this trial include those already receiving Gemcitabine for their pancreatic cancer without recent signs of progression. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking research.

You will need to stop taking any statin medications at least 2 weeks before starting the trial. The protocol does not specify other medications, so it's best to discuss your current medications with the trial team.

Research has shown that pitavastatin, a drug commonly used to lower cholesterol, might also reduce the risk of pancreatic cancer. Some studies found that people taking pitavastatin had a lower chance of developing pancreatic cancer and chronic pancreatitis, which is inflammation of the pancreas. This suggests the drug might be safe and could help manage cancer risk.

Pitavastatin is unique in the treatment of pancreatic cancer because it repurposes a cholesterol-lowering drug to target cancer cells. Most treatments for pancreatic cancer involve chemotherapy, which attacks rapidly dividing cells, but pitavastatin works by potentially disrupting the metabolism of cancer cells, which could hinder their growth. Researchers are excited about this approach as it offers a novel mechanism of action, potentially leading to more effective and less toxic treatment options. Additionally, being an oral medication, it provides a more convenient administration compared to traditional intravenous chemotherapy.

Research has shown that pitavastatin might lower the risk of pancreatic cancer by reducing inflammation, which is linked to cancer. In studies with mice, pitavastatin slowed pancreatic tumor growth and extended the mice's lifespan. Another study found that people taking pitavastatin had a lower risk of developing pancreatic cancer. These findings suggest that pitavastatin could help treat pancreatic cancer by reducing inflammation. Participants in this trial will receive different dosages of pitavastatin to evaluate its effectiveness and safety in treating pancreatic cancer.²³⁴⁶⁷